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ABSTRACT 
 
The frontotemporal dementia (FTD) spectrum is a heterogeneous group of neurodegenerative 
syndromes with overlapping clinical, molecular, and pathological features, all of which challenge 
the design of clinical trials in these conditions. To date, no pharmacological interventions have 
been proven effective in significantly modifying the course of these disorders. This study critically 
reviews the construct and methodology of previously published randomized controlled trials 
(RCTs) in FTD spectrum disorders in order to identify limitations and potential reasons for 
negative results. Moreover, recommendations based on the identified gaps are elaborated in order 
to guide future clinical trial design. A systematic literature review was carried out and presented 
in conformity with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
criteria. A total of 23 RCTs in cohorts with diagnoses of behavioural and language variants of 
FTD, corticobasal syndrome (CBS), and progressive supranuclear palsy syndrome were identified 
out of the 943 citations retrieved and were included in the qualitative review. Most studies 
identified were early-phase clinical trials that were small in size, short in duration, and frequently 
underpowered. Diagnoses of populations enrolled in clinical trials were based on clinical 
presentation and rarely included precision-medicine tools, such as genetic and molecular testing. 
Uniformity and standardization of research outcomes in FTD spectrum are essential. Several 
elements should be carefully considered and planned in future clinical trials. We anticipate that 
precision-medicine approaches will be crucial to adequately address heterogeneity in FTD 
spectrum research. 
P. Desmarais 3 
ABBREVIATIONS: 
AD = Alzheimer’s disease; ALS = amyotrophic lateral sclerosis; bvFTD = behavioural variant 
frontotemporal dementia; C9orf72 = chromosome 9 open reading frame 72 gene; CBD = 
corticobasal degeneration; CBS = corticobasal syndrome; CSF = cerebrospinal fluid; CT = 
computerized tomography; FTD = frontotemporal dementia; FTLD = Frontotemporal lobar 
degeneration; FUS = fused in sarcoma; GRN = progranulin gene; GWAS = genome-wide 
association study; lvPPA = logopenic variant primary progressive aphasia; MAPT = microtubule-
associated protein tau gene; MMSE = Mini-mental state examination; MRI = magnetic resonance 
imaging; MSA = multiple system atrophy; nfvPPA = nonfluent variant primary progressive 
aphasia; PET = positron emission tomography; PPA = Primary progressive aphasia; PSP = 
Progressive supranuclear palsy; RCT = randomized controlled trial; SPECT = single-photon 
emission computerized tomography; svPPA = Semantic variant primary progressive aphasia; 
TDP-43 = TAR DNA-binding protein 43. 
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GLOSSARY: 
 Frontotemporal dementia (FTD) – refers to the clinical diagnoses of behavioural variant 
FTD and primary progressive aphasia (i.e., semantic and nonfluent variants), which are mainly 
based on clinical manifestations and, sometimes, supported by the presence of characteristic 
cerebral hypometabolism, hypoperfusion, or atrophy on brain imaging. 
 Frontotemporal dementia spectrum – refers not only to the clinical diagnoses of 
behavioural variant FTD and primary progressive aphasia (i.e., semantic and nonfluent 
variants), but also to corticobasal syndrome, progressive supranuclear palsy syndrome, and 
amyotrophic lateral sclerosis. 
 Frontotemporal lobar degeneration (FTLD) – refers to neuropathological diagnoses where 
brain pathological examination reveals frontal and/or temporal lobe atrophy on macroscopy, 
and tau, TDP-43, or FUS immunoreactive inclusions on microscopy. For FTLD due to tau, 
subtypes include Pick’s disease, corticobasal degeneration, progressive supranuclear palsy, 
FTDP-17, globular glial tauopathy, and argyrophilic grain disease.  
 Patient-centred outcomes – refers to outcomes that are meaningful to patients, such as 
quality of life and autonomy. 
 Precision-medicine – refers to interventions individually tailored on the basis of a patient’s 
environmental exposure, lifestyle factors, genes, proteins, proteomics, and imaging. 
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INTRODUCTION 
 The frontotemporal dementia (FTD) spectrum encompasses a heterogeneous group of 
neurodegenerative syndromes presenting with a wide range of overlapping clinical features. FTD 
represents the second most common type of early-onset dementia, approaching the prevalence of 
Alzheimer’s disease (AD) in the 45-64 years age group. [1,2] It comprises two main clinical 
phenotypes: behavioural variant FTD (bvFTD), where behavioural changes and executive 
dysfunction are prominent early manifestations, and primary progressive aphasia (PPA), where 
comprehension and/or production of language are impaired. [3] PPA is further divided according 
to the specific language deficits into nonfluent variant PPA (nfvPPA) and semantic variant PPA 
(svPPA). Another subtype of PPA, logopenic variant (lvPPA), is more frequently associated with 
underlying Alzheimer’s pathology at autopsy. [4-6] Other FTD spectrum disorders include the 
clinical phenotypes of progressive supranuclear palsy syndrome and corticobasal syndrome 
(CBS). Motor manifestations, such as bradykinesia, rigidity, and dystonia, and cortical deficits 
such as apraxia are common manifestations during the course of these disorders. [7,8] Finally, 
amyotrophic lateral sclerosis (ALS) is also strongly linked to the FTD spectrum (i.e., 
frontotemporal dementia with motor neuron disease [FTD-MND]) as it shares common pathologic 
findings and genetic mutations. [9] About 10 to 15% of patients with ALS meet diagnostic criteria 
for FTD at baseline. [10] While each of these disorders has distinctive features and can be 
differentiated clinically from one another, there can be overlapping clinical features between the 
classic clinical phenotypes of FTD spectrum disorders, thus complicating the clinical diagnostic 
picture. 
 These neurodegenerative syndromes also share common underlying anatomical, 
molecular, and pathological substrates. Neuropathological examination of individuals with FTD 
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spectrum disorders reveals findings of frontotemporal lobar degeneration (FTLD), where atrophy 
is prominent in the frontal and/or temporal lobes. In most cases, neuronal loss and gliosis are 
thought to be secondary to neuronal and astrocytic inclusions of microtubule-associated protein 
tau, TAR DNA-binding protein 43 (TDP-43), and more rarely RNA-binding protein fused in 
sarcoma (FUS). [11-13] Behavioural and language variants of FTD are associated with tau, TDP-
43, or FUS proteinopathies, [14] and progressive supranuclear palsy syndrome is most often 
associated with tau proteinopathy, specifically progressive supranuclear palsy (PSP) pathology. 
[7,8] While CBS can also be secondary to tauopathy in the form of corticobasal degeneration 
(CBD) or PSP, other proteinopathies, such as beta-amyloidopathy/tauopathy (i.e., AD), 
prionopathy, TDP-43 proteinopathy, and alpha-synucleinopathy can also produce the syndrome. 
[8,15]  
 Genetic mutations inherited in an autosomal dominant fashion can cause FTD spectrum 
disorders, with 10-20% of all cases attributed to mutations in or near three different genes: C9orf72 
(encoding protein C9orf72), GRN (encoding progranulin), and MAPT (encoding microtubule-
associated protein tau). [11,14,16] Although more rare, other disease-causing genetic mutations 
have also been identified in heritable FTD, such as in VCP, TARDBP, TIA1, TBK1, and CCNF 
genes for cases of FTD due to TDP proteinopathy, and in CHMP2B and FUS for cases of FTD due 
to tau-negative, TDP-negative, ubiquitin-positive pathology. [17,18,19] For PSP and CBD not due 
to MAPT mutations (i.e., sporadic disease), common variation in MAPT, specifically the MAPT 
H1 haplotype, is an important genetic risk factor for these disorders. [20] Variants tagging the 
MAPT H1 haplotype were not surprisingly confirmed in a genome-wide association study 
(GWAS) of PSP, but several novel common variants in the STX6, EIF2AK3, and 
SLC25A38/Appoptosin genes were found to increase risk for this disease. [21,22] With respect to 
P. Desmarais 7 
sporadic TDP-43 proteinopathies and those caused by GRN mutations, common variants within 
the TMEM106B gene that increase its expression were found to increase risk and were associated 
with shorter disease duration in FTD cases; the major allele (T genotype) increased risk and was 
associated with a shorter disease duration, while the minor allele (G genotype) had protective 
effects. [23] In GRN carriers, the presence of the TMEM106B risk allele was also found to reduce 
the age of onset by approximately 13 years compared to those without it, [24] although this 
association was not confirmed in a recent GWAS study of GRN-related FTD. [25] In the latter 
study, another variant that leads to increased expression of the GFRA2 gene was also found to be 
associated with increased risk for GRN-related FTD. [25] The same major allele of TMEM106B 
associated with sporadic and GRN-related FTD also conferred an increased risk for C9orf72-
related FTD and FTD-MND, but not MND. [26] Interestingly, the same allele purported to be 
associated with shorter duration of disease in GRN-related FTD (T genotype) was associated with 
later age of onset and age of death in C9orf72-related FTD. [27]  
 Despite a better understanding of the pathophysiology and underlying genetic risk 
factors/modifiers of these disorders, evidence-based pharmacological interventions directed at 
mitigating their burden on patients are scarce. Currently, no intervention has been shown to alter 
the evolution of FTD spectrum disorders, and only a handful of small studies have demonstrated 
symptomatic benefits of pharmacologic interventions. [28] Designing interventional studies for 
these disorders is particularly challenging as a result of their low prevalence in the general 
population, insidious onset, and, in many cases, aggressive course. [3,9] Moreover, in the absence 
of widely accepted sensitive and specific diagnostic biomarkers, the various clinical phenotypes, 
genetic and pathological heterogeneity, and overlapping features of these disorders add to the 
complexity of designing valid clinical trials. Indeed, while the predictive value of established 
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international consensus diagnostic criteria for these disorders continues to improve with every 
iteration, [29-32] FTD spectrum disorders are frequently clinically misdiagnosed. [33] 
Furthermore, with various cognitive, neuropsychiatric, and motor manifestations, patients and 
caregivers’ needs are numerous and priorities difficult to establish. Finally, clinical heterogeneity 
makes it challenging for the development of meaningful clinical outcome measures that are 
sensitive to change across all of the diverse observed symptoms. 
 This article has several purposes. First, we present a critical review of the previously 
published randomized controlled trials (RCTs) of pharmacological interventions for FTD spectrum 
disorders wherein we: (1) describe the populations studied; (2) examine and analyze the design, 
methodology, and intervention applied in each trial, and; (3) synthesize all the various outcomes 
of interest investigated, as well as the endpoints measured to date. Second, we present 
recommendations for designing future clinical trials in FTD spectrum disorders based on 




 A pre-designed strategy was used for the literature search, study selection, data extraction, 
and data synthesis. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. [34] The protocol was registered prospectively on PROSPERO, 
where it can be retrieved and reviewed (registration number: CRD42018091194). 
Search strategy and selection criteria 
 We performed a systematic review of the literature by using the databases MEDLINE, 
EMBASE, and PsycINFO in order to identify RCTs of pharmacological interventions for the 
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treatment of FTD spectrum disorders, more specifically: behavioural and language variants of FTD 
(bvFTD, svPPA, and nfvPPA); PSP syndrome; and CBS. Although ALS shares some common 
molecular and genetic substrates with FTD disorders and, therefore, often overlaps clinically with 
them, we chose to exclude trials on this condition as the design and methodology of ALS trials 
have already been critically reviewed previously. [35] We used keywords including variations on 
“frontotemporal dementia” and “clinical trial” (see full search strategy in online supplementary 
information). We conducted our searches to retrieve articles from inception of databases up to 
January 1st, 2018, without restrictions on language. We manually searched the reference lists of 
relevant reports for additional citations to supplement our electronic search. Two reviewers (PD 
and QDN) performed the literature research in parallel and independently. Reviewers met and 
selected articles to be included in the present study. 
 Studies were included if they: (1) investigated the effects of a pharmacological 
intervention; (2) were carried out in a population with a FTD spectrum disorder; (3) and were 
randomized and controlled. Studies were excluded if they: (1) were observational/longitudinal 
studies, or; (2) represented only post-hoc analysis of previously published trials. Since the main 
purpose of our review was to identify limitations and gaps in previously published clinical trials, 
our selection process favoured inclusiveness. When disagreement arose between reviewers on 
studies to be included in the qualitative review, a third reviewer (MM) resolved the discrepancy.  
Data extraction, quality assessment, and statistical analysis 
 Data were abstracted in duplicate, concomitantly, and independently by two trained 
investigators using a standard data abstraction form. Data pertaining to study’s design (e.g., 
condition studied, number of arms, type of intervention, comparator, eligibility criteria, primary 
and secondary endpoint measurements), the population (e.g., size of groups, mean age and 
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standard deviation, percentage of females), trial’s main conclusions, as well as the journal and date 
of publication were collected. Study quality was assessed with the Cochrane instrument to assess 
the risk of bias. [36] When disagreements arose in coding, resolution was obtained through 
consensus. We performed descriptive statistics using IBM ® SPSS ® Statistics 24.0 (IBM corp. 
Armonk, NY). [37] 
RESULTS 
Search results and study characteristics 
 A total of 947 abstracts were identified, of which, 75 citations were reviewed at the full-
text stage (see online supplementary figure S1 for the PRISMA flow chart). Of the articles 
reviewed in their entirety, 52 did not meet inclusion criteria and were excluded. The 23 remaining 
articles were included in the present qualitative synthesis (Table 1). [38-60] Risk of bias in the 
included studies was perceived as low (see online supplementary data). From 1998 to 2016, a total 
of 1,362 participants (44% females) with a FTD spectrum disorder were randomized to clinical 
trials. BvFTD and PSP syndrome were the most studied clinical conditions with 12 trials (52%) 
and 11 trials (48%) published, respectively. Three trials (13%) included participants with different 
subtypes of PPA. No interventional trial involving participants with CBS was identified. Of note, 
a large unpublished clinical trial of leuco-methylthioninium was also identified and involved 220 
participants with a diagnosis of bvFTD. [S61] The largest trial in size for PSP syndrome also 
included participants with multiple system atrophy (MSA), with 363 PSP syndrome (47%) and 
404 MSA (53%) participants. [50] Most trials were small in size, with only 3 trials (13%) having 
randomized more than 100 participants.  
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Table 1. RCTs of pharmacological interventions in FTD spectrum disorders 
Study Condition studied Cohort size  Trial design Intervention Control Length Outcome of interest 
Leclair-Visonneau et al, 2016 [38] PSP syndrome 28 DB, PG, MC 
Sodium valproate 
1,500 mg/day 
Placebo 24 months Symptom progression 
Nuebling et al, 2016 [39] PSP syndrome 44 DB, PG, SC 
Rasagiline 
1 mg/day 
Placebo 12 months Symptom progression 
Apetauerova et al, 2016 [40] PSP syndrome 61 DB, PG, MC 
CoQ10 
2,400 mg/day 
Placebo 12 months 
Safety and efficacy on disease 
progression 
Pardini et al, 2015 [41] BvFTD 26 SB, CX, SC 
SouvenaidTM 
125 ml/day 
Placebo 12 weeks Frontal lobe function 
Hughes et al, 2015 [42] BvFTD 12 DB, CX, SC 
Citalopram 
Single dose 30 mg 
Placebo 2 sessions* Frontal lobe function 
Finger et al, 2015 [43] BvFTD and SD 23 DB, PG, SC 
Oxytocin 
24, 48, 72 IU BID 
Placebo 1 week 
Safety and tolerability, 
Symptom progression 
Tolosa et al, 2014 [44] PSP syndrome 146 DB, PG, MC 
Tideglusib 
600 or 800 mg/day 
Placebo 52 weeks Safety and disease progression 
Höglinger et al, 2014 [45]** PSP syndrome 37 DB, PG, MC 
Tideglusib 
600 or 800 mg/day 
Placebo 52 weeks 
Disease progression on brain 
imaging 
Boxer et al, 2014 [46] PSP syndrome 313 DB, PG, MC 
Davunetide 
30 mg BID 
Placebo 52 weeks 
Safety and efficacy on disease 
progression  
Boxer et al, 2013 [47] BvFTD and SD 81 DB, PG, MC 
Memantine 
10 mg BID 
Placebo 26 weeks Symptom progression 
Jesso et al, 2011 [48] BvFTD 20 DB, CX, SC 
Oxytocin 
Single dose 24 IU 
Placebo 1 week Emotion recognition 
Vercelletto et al, 2011 [49] BvFTD 52 DB, PG, MC 
Memantine 
10 mg BID 
Placebo 52 weeks Symptom progression 
Bensimon et al, 2009 [50] PSP syndrome and MSA 
767  
(363 with PSP) 
DB, PG, MC 
Riluzole 
50-200 mg/day 
Placebo 35 months 
Survival and disease 
progression 
Stamelou et al, 2008 [51] PSP syndrome 21 DB, PG, SC 
CoQ10 
5 mg/kg/day 
Placebo 6 weeks 
Symptom progression and 
energy metabolite on MRS 




OL: 18 weeks 
DB: 8 weeks 
Symptom progression 
Rahman et al, 2006 [53] BvFTD 8 DB, CX, SC 
Methylphenidate 
Single dose 40 mg 
Placebo 2 sessions* Frontal lobe function 
Deakin et al, 2004 [54] BvFTD 10 DB, CX, SC 
Paroxetine 
40 mg/day 
Placebo 7 weeks Frontal lobe function 





12 months Symptom progression 
Lebert et al, 2004 [56] BvFTD 31 DB, CX, MC 
Trazodone 
300 mg/day 
Placebo 6 weeks Symptom progression 





14 months Symptom progression 
Litvan et al, 2001 [58] PSP syndrome 21 DB, CX, SC 
Donepezil 
10 mg/day 
Placebo 6 weeks Symptom progression 
Frattali et al, 1999 [59] PSP syndrome 6 DB, CX, SC 
Physostigmine 
0.5-2 mg q2hr 
Placebo 3-4 days Oral motor functions 
Rascol et al, 1998 [60] PSP syndrome 14 DB, CX, MC 
Efaroxan 
2 mg TID 
Placebo 6 weeks Motor symptom progression 
CX, crossover; BvFTD, behavioural variant frontotemporal dementia; DB, double-blind; FTD, frontotemporal dementia; OL, open-label; MC, multicenter; MRS, magnetic resonance spectroscopy; NS, not 
specified; MSA, multisystem atrophy; PG, parallel group; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy; SB, single-blind; SC, single center; SD, semantic dementia. *Studies 
involved administration of a single dose of the investigational drug or placebo followed by same day cognitive assessment. ** This was a sub-study of the above study [45]. 
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 Several different drugs and regimens have been investigated as potential symptomatic 
therapies, with acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine) being 
the most frequently investigated drugs, followed by antidepressants (citalopram and paroxetine) 
and oxytocin, a neuropeptide (see online supplementary table S1). Investigations for potential 
disease-modifying agents were mainly performed in PSP syndrome and included coenzyme Q 10 
(CoQ10), [40,51] davunetide, [46] rasagiline, [39] riluzole, [50] sodium valproate, [38] and 
tideglusib. [44,45] A crossover design was used in 9 trials (39%), specifically for 6 symptomatic 
drug trials and 3 disease-modifying drug trials. Duration of interventions was shorter than 3 months 
for more than half of trials (52%). 
Eligibility criteria in clinical trials 
 A summary of the main eligibility criteria for enrolment in these clinical trials is provided 
in Table 2. For studies carried out in bvFTD, 7 trials (58%) reported age requirements for inclusion, 
with minimum age for inclusion ranging from 30 to 60, and maximum age for inclusion ranging 
from 65 to 80. Eight trials (67%) explicitly excluded participants with advanced disease defined 
by the presence of significant cognitive impairment. However, only 4 trials reported a specific 
threshold score for exclusion, which was based on the Mini-Mental State Examination (MMSE). 
Confirmatory abnormality on brain imaging, mainly frontotemporal atrophy, was the only 
biomarker requirement retrieved in the included clinical trials and was explicitly required for 
enrolment in 7 of the bvFTD trials (58%). The scales used to assess severity of brain atrophy on 
imaging were not explicitly reported in the published articles, while the unpublished clinical trial 
in bvFTD [S61] enrolled participants with evidence of frontal and/or temporal lobe atrophy on 
MRI at Kipps level 2 or greater. [S62] None of the trials in bvFTD reported subsequent 
pathological confirmation following clinical diagnosis. 
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Table 2. Eligibility and clinical diagnostic criteria of FTD spectrum disorders used in RCTs 




exclusion Biomarkers used for inclusion* 
Pathology 
confirmation  
Behavioural variant FTD 
Pardini et al. [41] Rascovsky 2011 50-65 NS None No 
Hughes et al. [42] 
Probable bvFTD 
Rascovsky 2011 
NS NS Abnormal brain imaging No 
Finger et al. [43] 
Probable bvFTD 
Rascovsky 2011  
30-80 
“Disease severity too 
advanced to participate” 
Neuroimaging supports diagnosis (CT, 
MRI or SPECT) 
No 
Boxer et al. [47] Neary 1998 40-80 MMSE < 15 Characteristic brain atrophy No 
Jesso et al. [48] Neary 1998 NS 
“Comprehension deficits or 
language impairment” 
MRI, CT or SPECT imaging consistent 
with diagnosis 
No 
Vercelletto et al. [49] Neary 1998 45-75 MMSE < 19 None No 
Kertesz et al. [52] Neary 1998 30-80 MMSE ≤ 5 
Frontotemporal lobar atrophy on 
imaging 
No 
Rahman et al. [53] The Lund and Manchester Groups 1994 NS MMSE ≤ 20 None No 
Deakin et al. [54] Neary 1998 NS NS None No 
Moretti et al. [55] The Lund and Manchester Groups 1994 60-75 “Significant impairment” Frontal cortex atrophy on imaging No 
Lebert et al. [56] The Lund and Manchester Groups 1994 NS NS None No 
Moretti et al. [57] The Lund and Manchester Groups 1994 60-70 “Significant impairment” Frontal cortex atrophy on imaging No 
BvFTD; behavioural variant frontotemporal dementia; MMSE, mini mental state examination; MRI, magnetic resonance imaging; NS, not specified; SPECT, single-photon emission computed 
tomography.*Possible biomarkers such as findings on structural or functional brain imaging, cerebrospinal fluid, or genetic mutations.  
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Table 2. Continued 




exclusion Biomarkers used for inclusion 
Pathology 
confirmation 
Primary progressive aphasia 
Finger et al. [43] 
Semantic aphasia (with behavioural features) 
Neary 1998 
30-80 
“Disease severity too 
advanced to participate” 
Neuroimaging supports diagnosis (CT, 
MRI or SPECT) 
No 
Boxer et al. [47] 
Semantic aphasia 
Neary 1998 
40-80 MMSE < 15 Characteristic brain atrophy No 
Kertesz et al. [52] Mesulam 1987 30-80 MMSE ≤ 5 
Frontotemporal lobar atrophy on 
imaging 
No 
Progressive supranuclear palsy syndrome 
Leclair-Visonneau et al. [38] 
Possible or probable PSP  
Litvan 1996 
45-75 MMSE ≤ 22 None No 
Nuebling et al. [39] 
Propable PSP 
Litvan 1996 
50-80 MMSE ≤ 24 None No 
Apetauerova et al. [40] 
Probable PSP 
Litvan 1996 
≥ 40 NS None No 
Tolosa et al. [44] 
Possible or probable PSP 
Litvan 1996 
40-85 NS 
MRI consistent with PSP and ruling out 
relevant vascular pathology  
No 
Höglinger et al. [45] 
Possible or probable PSP 
Litvan 1996 
40-85 NS 
MRI consistent with PSP and ruling out 
relevant vascular pathology 
No 
Boxer et al. [46] 
Probable or possible PSP 
NNIPPS 2009  
41-85 MMSE < 15 None No 
Bensimon et al. [50] 
Simplified operational diagnostic criteria 
(NNIPPS) from consensus criteria (Litvan 
1996 & 2003) 
≥ 30 NS None 
Histopathological 
analysis of 112/767 
cases: 94% correct 
Stamelou et al. [51] 
Probable PSP 
Litvan 1996 
≤ 85 MMSE ≤ 24 None No 
Litvan et al. [58] 
Possible or probable PSP 
Litvan 1996 
NS 
“Absence of frontal, 




analysis of 4/21 cases: 
100% correct 
Frattali et al. [59] Based on Litvan 1996 ≥ 50 NS None No 
Rascol et al. [60] Lees 1987 40-80 
“Not severely demented 
according to DSM-IV 
criteria” 
None No 
MMSE, mini mental state examination; MRI, magnetic resonance imaging; NS, not specified; NNIPPS, neuroprotection and natural history in Parkinson plus syndromes; PSP, progressive 
supranuclear palsy; SPECT, single-photon emission computed tomography. *Possible biomarkers such as findings on structural or functional brain imaging, cerebrospinal fluid, or genetic 
mutations. 
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 For studies carried out in PPA, all 3 trials (100%) reported the use of age requirements, all 
excluding participants aged 80 years and older. Participants with advanced disease, defined by 
significant cognitive impairment on cognitive screening tests, were also excluded from these trials, 
with 2 trials (66%) reporting a specific MMSE threshold score for exclusion. The clinical diagnosis 
of enrolled PPA cases was supported by the presence of neuroimaging abnormalities, such as 
frontotemporal atrophy or hypoperfusion. The scales used to assess brain atrophy or hypoperfusion 
on imaging were not explicitly reported. None of the trials reported subsequent pathological 
confirmation following clinical diagnosis. 
 For studies conducted in PSP syndrome, all trials except one explicitly reported the use of 
age requirements for inclusion of participants. Six trials (55%) excluded participants with 
significant cognitive impairment, with 4 trials (36%) using a specific MMSE threshold score. Only 
2 trials (18%) explicitly reported the use of neuroimaging for corroboration of clinical diagnosis. 
Finally, 2 trials (18%) mentioned subsequent pathological confirmation of the clinical diagnosis 
for a portion of the included participants. 
Outcomes of interest and endpoint measures in clinical trials 
 Several different main outcomes of interest related to cognitive, language, 
neuropsychiatric, and motor manifestations have been investigated in these clinical trials (Table 
1). Similarly, the effects of investigational drugs on the progression of symptoms were assessed 
through the use of various different scales and tools. The various scales and tools that have been 
utilized in these studies are reported in online supplementary table S2.  
 All clinical trials in bvFTD but one focused on the treatment of neuropsychiatric 
symptoms, with the Neuropsychiatric Inventory (NPI) [S63] and Frontal Behavioural Inventory 
(FBI) [S64] being the most commonly utilized tools. The other trial [53] investigated specifically 
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the effect of methylphenidate on decision-making behaviour. Several scales and tools in regard to 
social cognition have also been utilized, including the Reading the Mind in the Eye Test (RMET), 
[S65] the Interpersonal Reactivity Index (IRI), [S66] and Facial Expression Recognition task. 
[S67] There were a variety of outcomes in clinical trials in PPA, including management of 
neuropsychiatric symptoms and palliation of language difficulties. All clinical trials in PSP 
syndrome except one explored the effects of investigational drugs on motor symptoms with the 
use of motor scales, with the PSP - Rating Scale (PSPRS) and the Unified Parkinson’s Disease 
Rating Scale (UPDRS) being the most commonly utilized tools. One trial [59] investigated 
specifically the effect of physostigmine on swallowing abilities. In regard to patient-centred 
outcomes, 3 trials (25%) in bvFTD and 2 trials (66%) in PPA reported measurements related to 
these, including tolerability of drug and impact on functional independency. In PSP syndrome, 9 
trials (82%) reported patient-centred outcomes, such as quality of life, autonomy, and tolerability 
of treatment. Finally, only 3 trials (13%), all conducted in bvFTD, reported caregiver-related 
outcomes, such as caregiver burden. 
DISCUSSION 
Heterogeneity in clinical trials  
 This systematic review of RCTs of pharmacological therapies for FTD spectrum disorders, 
with a focus on methodology, highlights some of the current challenges in designing and 
conducting clinical trials in these conditions. The significant heterogeneity in design and 
methodology of the identified clinical trials reflects the complexity of these syndromes and their 
underlying pathologies. Participants with different clinical phenotypes have been enrolled in these 
studies using diverse eligibility criteria based on the clinical diagnosis, age at baseline, as well as 
the presence or absence of certain cognitive deficits. Numerous drugs with different 
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pharmacodynamic and pharmacokinetic properties have been investigated as potential disease-
modifying interventions or symptomatic treatments of diverse symptoms and deficits (online 
supplementary table S1). Similarly, numerous tools and scales with different psychometric 
properties have been used to measure the effects of these investigational drugs (online 
supplementary table S2). 
Limitations and challenges  
 Several limitations have been identified in these clinical trials, some of which could explain 
their negative results. First, clinical diagnosis for enrolment was not always detailed or clearly 
reported in the studies. This could be partly explained by the fact that terminology has significantly 
evolved over the past decade as our understanding and conceptualization of these disorders have 
improved. As well, inclusion of participants with concomitant motor neuron disease was only 
reported explicitly in one study. [47] Second, the use of biomarkers for corroboration of clinical 
diagnosis, or for exclusion of other neurocognitive disorders, was limited to the presence or 
absence of typical brain imaging abnormalities, mainly cerebral atrophy on CT scans and/or MRI, 
hypometabolism on FDG-PET scans, or hypoperfusion on SPECT scans in frontotemporal 
regions. With the notable exception of the Kipps scale used in one study [S61], the specific tools 
to assess brain imaging abnormalities were rarely reported in the retrieved studies. None of the 
trials explicitly reported the use of, for instance, cerebrospinal fluid analysis (CSF) or genetic 
testing for assessing the eligibility of participants. However, it must be stated that most of these 
clinical trials predated the discovery of genetic and other potential biomarkers.  
 Current international consensus clinical diagnostic criteria have limitations, as 
demonstrated in studies on neurocognitive disorders such as AD, Parkinson’s disease dementia, 
and bvFTD. [S68-S71] Clinical diagnoses do not always match the final pathology results, with 
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reported inaccurate diagnosis of AD pathology ranging from 19% to 45% in one cohort study. 
[S68] While recent iterations of clinical diagnostic criteria for FTD spectrum disorders have 
increased their sensitivities, such as Rascovsky’s criteria improving from previous diagnostic 
criteria of bvFTD (86% compared to 53% sensitivity), [30] current criteria tend to have higher 
specificities than sensitivities. [29-32] Thus, patients with some classical features of FTD may not 
meet the full criteria for diagnosis [S72] or can meet more than one criterion across different 
syndromes. [S71] Furthermore, multiple comorbid neurodegenerative and non-neurodegenerative 
findings may be present at autopsy. [S73-S77] For instance, α-synucleinopathies (24.9%), 
tauopathies (23.2%), TDP-43 proteinopathy (13.3%) and vascular lesions (48.9%) were identified 
in the brains of elderly individuals with and without dementia in a large community-based autopsy 
series. [S73] Hence, definitions of neurodegenerative disorders based exclusively on clinical signs 
and symptoms may not fully grasp the heterogeneity of underlying pathologies. Third, clinical 
trials in bvFTD where brain atrophy on imaging was not required for participants’ eligibility may 
have unintentionally randomized phenocopy cases. These slowly progressive and sometimes non-
progressive cases, which fulfill the neuropsychological and neuropsychiatric criteria for bvFTD, 
appear to be neuropathologically distinct from other forms of FTD at autopsy, with the notable 
exception of C9orf72 mutation cases. [S78] Previously enrolled participants of RCTs may not have 
had the expected underlying pathology, thus the drug being tested might have been off target. 
Fourth, most of the retrieved studies were early-phase clinical trials aimed at assessing safety and 
tolerability, hence their short durations and small cohort sizes. These could preclude the detection 
of a treatment effect especially relating to disease modification, which would need potentially a 
longer observation period. With the exception of a few multicenter trials that were able to recruit 
larger cohorts, most clinical trials identified were small in size and may have lacked statistical 
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power. Single-center trials often had a crossover design while multicenter trials had a classic 
placebo-controlled parallel-group design. Fifth, previous RCTs of pharmacological interventions 
may have been attempted too late in the course of the disease, potentially missing the therapeutic 
window of opportunity. Finally, selected tools and clinical scales used to measure treatment effect 
may not have been sensitive enough to capture significant changes in symptoms or disease 
progression as they may not cover effectively all of the various clinical manifestations of the FTD 
spectrum or fail to take into account the functional-anatomical specificity of the frontal regions. 
Addressing limitations and moving forward 
 In the context of complex clinical manifestations and pathological heterogeneity, 
uniformity and standardization in future clinical trials for FTD spectrum disorders are needed. 
Precision-medicine approaches, where interventions are designed by considering the patient’s 
specific clinical syndrome as well as disease profile in regard to its underlying molecular and 
genetic signatures, offer opportunities to address some of the current challenges. The following 
elaborated recommendations for future clinical trials in FTD spectrum disorders should be 
considered (see Table 3).  
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Table 3. Recommendations for future clinical trials in FTD spectrum disorders 
Element Recommendations and examples 
Diagnosis Investigators should clearly state if participants enrolled in the clinical trial have a: 
 Clinical diagnosis according to current international consensus diagnostic criteria, such as: 
o Probable bvFTD according to Rascovsky 2011 criteria 
 Molecular findings supportive of FTLD or absence of biomarkers suggestive of another 
diagnosis, such as: 
o Hypometabolism on PET-scan suggestive of FTD 
o Cerebral atrophy in frontotemporal regions suggestive of FTD 
o Negative amyloid PET imaging 
 Genetic diagnosis according to the presence of a known disease-causing mutation, such as: 
o Common gene mutations: C9orf72, GRN, MAPT 
o Rare gene mutations: VCP, TARDBP, TIA1, TBK1, CCNF, FUS, CHMP2B 
 Histopathological diagnosis, such as: 
o Subsequent autopsy confirmation of clinical diagnosis 
If participants have a molecular, genetic, or histopathological diagnosis, it should be stated if 
participants are asymptomatic/presymptomatic or symptomatic. 
The natural disease progression of enrolled participants should be carefully examined to 
determine whether it is slowly or rapidly progressing. 
The presence of concomitant motor neuron disease should be reported. 
Study design Innovative study design and methodology should be considered in order to maximize chance of 
capturing positive effects: 
 International multicenter trials should be prioritized, such as: 
o The GENFI cohort 
o The LEFFTDS cohort 
o The ARTFL cohort 
 Platform trials, multi-interventional, multi-arm trials should be considered, such as: 
o Multiple molecular targets 
o Combination therapies 
o Non-pharmacological intervention with pharmacological intervention 
 Collaboration between the pharmaceutical industry, clinicians, clinical trial statisticians, 
statistical geneticists, and bioinformaticians should be promoted; 
 Interventional trials in presymptomatic high-risk participants should be attempted; 
 Pre-specified post-hoc analyses should be considered to find subgroup responders. 
Interventions should be clearly defined as to whether they are preventive, disease-modifying, 
and/or symptomatic in nature. 
Eligibility criteria Inclusion and exclusion criteria should be clearly reported and justified. The following variables 
should be carefully addressed: 
 Minimum and maximum age limits should be justified;  
 Adequate sex representation should be sought by avoiding exclusion criteria that preferentially 
affect one sex over the other; 
 Significant cognitive impairment precluding randomization should be carefully defined and 
justified; 
 Non-FTD cases should be excluded through the use of biomarkers such as CSF amyloid beta 
or amyloid PET imaging. 
BvFTD, behavioural variant frontotemporal dementia; CSF, cerebrospinal fluid; GENFI, genetic frontotemporal dementia 
initiative; FTD, frontotemporal dementia; LEFFTDS, longitudinal evaluation of familial frontotemporal dementia subjects; 
nfvPPA, nonfluent variant primary progressive aphasia; PET, positron-emission tomography; NNIPPS, neuroprotection and 
natural history in Parkinson plus syndromes. Italicized items in the table represent examples. 
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Table 3. Continued 
Element Recommendations and examples 
Outcome of interest Investigators should clearly state outcomes of interest of the study and whether they pertain to: 
 Patient-centred and/or caregiver-centred outcomes, such as: 
o Quality of life 
o Caregiver burden 
o Autonomy/independency  
o Risk of institutionalization 
 Surrogate outcomes, such as: 
o Brain atrophy on imaging 
o Tau brain deposits on imaging 
o Progranulin plasma level 
 Symptomatology: 
 Cognitive outcomes, such as: 
o Frontal lobe functions 
o Language 
 Neuropsychiatric outcomes, such as: 
o Apathy and disinhibition 
o Depression 




Patients, families, and caregivers should be involved in the decision-process of selecting and 
prioritizing future clinical trials’ main goals. 
Endpoint measure 
and effect assessment 
Several accurate and validated tools and scales should be utilized, in combination with more 
commonly used clinical scales, in order to encompass diseases heterogeneity, including global 
and specific scales: 
 Disease-specific scales, such as: 
o CDR-FTLD  
o PSPRS 
 Symptoms and deficits severity: 
 Cognitive scales; 
o General cognitive scales, such as: DRS, MoCA 
o Specific cognitive domain tools, such as:  
 Processing speed: Simple Reaction Time, Choice Reaction Time 
 Attention and working memory: Forward digit span, Backward digit span 
 Executive functioning: Stroop Task, Trail-Making Test, Verbal Fluency 
 Language: Boston Naming Test, Western Aphasia Battery 
 Social cognition: ToM Tasks, Interpersonal Reactivity Index 
 Neuropsychiatric scales, such as: 
o FBI 
o NPI 
 Motor measures, such as: 
o Time to wheelchair-bound 
o Time to unintelligible speech 
o UPDRS score 
Multidimensional patient and caregiver-reported measures should be included in the treatment 
effect assessment, including functional and quality of life scales. 
Potential differential effect of the investigational drug should be sought in subgroup analysis or 
by including the following variables as covariates of interest: 
 Age; 
 Sex; 
 Genetic variants, such as: 
o MAPT H1 haplotype 
o TMEM106B genotype 
 Co-pathology. 
CDR-FTLD, clinical dementia rating scale – frontotemporal lobar degeneration; DRS, dementia rating scale; FBI, frontal 
behavioural inventory; MoCA, Montreal cognitive assessment; NPI, neuropsychiatric inventory; ToM, theory of mind; 
UPDRS, unified Parkinson’s disease rating scale. Italicized items in the table represent examples. 
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 The diagnoses of participants enrolled in clinical trials and their supportive findings should 
be clearly defined and reported. Initial clinical diagnoses should be prospectively reassessed as 
participants’ clinical presentation may change over time. [S71,S79-S81] Additionally, subsequent 
pathological confirmation of participants’ diagnoses should be attempted whenever possible. This 
could be facilitated by systematically discussing brain donation with every eligible participant 
before enrolment in a clinical trial. FTD spectrum disorders have a wide range of clinical 
manifestations, which frequently overlap with each other. [3,33] Therefore, investigations 
allowing exclusion of other disorders that may mimic FTD spectrum disorders, such as other 
neurodegenerative disorders (e.g., AD), psychiatric disorders, and vascular disease should be 
rigorously performed. [8,14,33,S75,S76] As well, phenocopies of bvFTD should also be identified 
as they can also contribute to pathological misclassification in clinical trials. [S82] Although it 
may be difficult to accomplish this before randomization, clinical suspicion should increase in the 
context of participants with non-progressive conditions. FTD spectrum disorders are biologically 
heterogeneous, involving several different pathological inclusion proteinopathies, variants and 
subtypes, and cerebral topographies, which should all be considered in clinical trials. [11,14,S83-
S87] Although there are still no widely accepted biomarkers that are both sensitive and specific, 
some molecular and genetic findings could potentially be used as eligibility criteria for clinical 
trials in FTD spectrum disorders. Possible examples include plasma progranulin levels, where 
decreased levels can predict the presence of GRN mutations, [S88-S92] and plasma and CSF 
neurofilament light chain protein levels, where levels could reflect disease severity. [S93-S96] In 
the (hopefully) near future, a tau-ligand PET-scan could help increase accuracy of clinical 
diagnoses, where FTLD cases due to TDP-43 proteinopathy would be PET negative and cases due 
to tauopathy would be PET positive. [S97-S100] Considering the important contribution of genetic 
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mutations and variants to these disorders, genetic testing should be an integral part of the selection 
process of participants. [S101-S104] A known genetic profile is informative of the expected 
natural progression of the underlying disorder. For instance, C9orf72 promoter hypermethylation 
is associated with prolonged disease duration in expansion carriers. [S105-S106] Although 
uncommon, the possibility of co-occurrence of genetic mutations should also be considered, such 
as C9orf72 repeat expansion carriers also harbouring GRN or MAPT gene mutations. [S107] 
Moreover, molecular and genetic factors could potentially represent interesting targets for future 
drugs, such as the open-label trial of nimodipine in progranulin deficiency, [S108] as well as 
markers of pharmacological response or adverse effects, similar to previously identified genetic 
drug response markers in Parkinson’s disease. [S109] With improvement of target engagement, 
specifying whether the diagnosis of a participant is based solely on clinical signs or in conjunction 
with molecular, genetic, or histopathological findings is essential as these markers significantly 
improves the prediction of the correct underlying pathological process and, hence, the presence of 
the pharmacological target (see Figure 1). 
 Different clinical trials should involve participants at diverse stages of the disease, 
including presymptomatic stages. Similar to AD, FTD spectrum disorders progress over years 
before clinical manifestations and brain changes such as hypometabolism, hypoperfusion, and 
atrophy become apparent (see Figure 2). [S110, S111] Although penetrance of known mutations 
may vary considerably according to several factors (e.g., TMEM106B genotype), future clinical 
trials should investigate potential disease-modifying interventions in high-risk asymptomatic 
individuals, who are mutation carriers. Identifying and recruiting presymptomatic individuals in 
studies may be difficult but is feasible, as demonstrated by the Genetic Frontotemporal Dementia 
Initiative (GENFI), [S111] the Longitudinal Evaluation of Familial Frontotemporal Dementia 
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Subjects (LEFFTDS), [S112] and the Advancing Research and Treatment for FTLD (ARTFL) 
studies. [S113]  
 Since FTD spectrum disorders have a low prevalence and incidence in the general 
population compared to AD, [1,2] innovative methodologies and study designs should be sought. 
Statistically meaningful results require enrolment of a sufficient number of participants. Therefore, 
international initiatives and collaborations, such as the NNIPPS study [50] and “clinical trial 
ready” cohorts such as GENFI, [S111] LEFFTDS, [S112] and ARTFL, [S113] are essential to test 
new clinical questions and to establish biomarkers that can be used as outcome measures. 
Initiating, implementing, and maintaining international networks come with challenges and 
obstacles, such as additional financial costs, cultural and language differences, and data 
transmission issues, just to name a few. But these collaborations are highly valuable in the long 
run. The Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU) represents an example 
of a successful international clinical trial in autosomal dominant AD. [S114] International research 
registries and networks facilitate recruitment of potential research participants and promote 
alliances between healthcare providers and researchers. 
 Conducting adaptive clinical trials with Bayesian models and platform trials, such as the 
Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE), [S115] are 
interesting avenues to investigate multiple prospective pharmacological interventions aimed at 
specific target points in a short amount of time. [S116,S117] Furthermore, in the absence of 
effective treatments, pharmacological and non-pharmacological interventions, such as exercise, 
should be co-investigated in parallel and in combination in order to maximize chances of 
identifying interventions with symptomatic benefits. Successful drug-tailoring for rare diseases is 
possible, such as it was recently done in spinal muscular atrophy with the development of 
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nusinersen, an antisense oligonucleotide drug. [S118,S119] Similar to therapies in oncology and 
microbiology, administration of several drugs with different pharmacodynamic properties in 
combination may be necessary in order to have a disease-modifying effect in FTD spectrum 
disorders. 
 Exclusion criteria should be carefully planned so as not to exclude certain subgroups of 
individuals. Historically, females [S120,S121] and elderly [S122-S125] have been 
underrepresented in clinical trials. There is evidence of sex differences in the clinical 
manifestations of genetic mutations in FTD, which could translate into differential treatment 
effects. [S126] Specifically, there appears to be a higher prevalence of female patients with GRN-
related FTD [S126] indicating that future clinical trials in GRN-related FTD should adjust for 
potential sex effects. Although exclusion of participants with advanced age can be justified by the 
increased prevalence of comorbid cerebral pathology, [S73,S76,S127-S129] the higher risk of 
adverse effects of investigational drugs, [S130,S131] and different progression rates of diseases, 
[S132,S133] differential treatment effects should be explored by subgroup analyses. Older age at 
onset may also increase the likelihood of a FTD case being sporadic where underlying pathologies 
and risk factors are different than those in early-onset cases, which may be more likely to have an 
identifiable genetic mutation. Similarly, exclusion of participants with cognitive impairment 
should be clearly justified. Cognitive deficits are nearly universal during the course of FTD 
spectrum disorders and the ideal screening tool and threshold score for inclusion/exclusion remain 
to be determined. The MMSE is not the most sensitive nor specific screening tool for the 
assessment of cognitive deficits in these disorders. [S134,S135] As well, the MMSE may not be 
discriminative enough to help in determining the stage of these disorders early in their course. For 
instance, language impairment affects the assessment of other cognitive domains and the use of a 
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specific threshold score for inclusion may inappropriately exclude participants with aphasia from 
clinical trials, despite them having little or no other important cognitive or behavioural impairment. 
[S135]  
 Researchers should prioritize the investigation of pharmacological interventions aimed at 
patient-centred and caregiver-centred outcomes. There is currently an unmet need for effective 
symptomatic therapies at all stages of these disorders. Patients, families, and caregivers should be 
involved as research partners in the decision-process in order to identify and prioritize goals to 
pursue in future clinical trials. The Association for FTLD, the FTD Disorders Registry, and the 
FTD Treatment Study Group are all encouraging these and other partnerships. As well, studies 
should clearly define and report whether the outcomes of interest of the investigated treatment 
relate to prevention, symptomatic relief, and/or disease modification. Clinical trials with longer 
observation periods should be undertaken in order to capture disease-modifying effects of 
investigational drugs.  
 FTD spectrum disorders have various cognitive, neuropsychiatric, and motor 
manifestations, which may require different pharmacological interventions to treat them and, 
consequently, necessitate different assessment tools and scales to measure the effects of the 
interventions. Tools specifically designed for FTD spectrum disorders, which take into 
consideration the various manifestations of these disorders (i.e., global composite measures), 
should be prioritized, such as the Clinical Dementia Rating scale – FTLD (CDR-FTLD) [S136-
S138] and the PSPRS. [S139,S140] Tools assessing disease severity in specific domains, such as 
frontal system functions, should be used in conjunction. [S141] As well, it should be acknowledged 
that some clinical manifestations may interfere with the assessment of several other cognitive, 
neuropsychiatric, and motor impairments, affecting interpretation of results. Functional scales 
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taking this fact into consideration should also be prioritized, such as the CBD – Functional Rating 
Scale (CBD-FS). [S142] Multidimensional patient-reported and caregiver-reported measures 
should likewise be integrated in future clinical trials. An interesting avenue includes the Goal 
Attainment Scaling instrument, which is a personalized outcome measure where patients and 
caregivers set the treatment goals. [S143] Another alternative approach to identifying a treatment 
effect is to capture change in symptoms and functions using a variety of different rating 
instruments previously used, but then to identify a composite clinical effect through the use of 
eigenfunctions and multifactor dimensionality reduction approaches applied to the comprehensive 
dataset collected. In addition, change in neuroimaging measures over time, especially in the case 
of presymptomatic prevention trials, should also be explored as a potential outcome measure to 
consider in conjunction with clinical measures. These include reduction in rate of atrophy on MRI, 
and reduction in tau burden on PET (once a viable tracer has been validated). Furthermore, 
increases in plasma and/or CSF progranulin levels for GRN-related FTD may also be a possible 
treatment goal, although there has not been a good correlation observed between disease measures 
and progranulin levels to date. In addition, the arrival of new technologies to assist with the 
assessment and monitoring of individuals with cognitive and functional deficits, such as wearable 
devices, is an exciting moment in dementia research and could offer novel ways to capture the 
effects of clinical interventions in the near future. 
 Finally, with our increased understanding of rare, causative mutations for genetic FTD and 
common genetic variation that increases risk for sporadic FTD or that modifies its course in 
genetically-confirmed or sporadic cases, clinical trial design should consider stratified designs 
based on the presence of an autosomal dominantly inherited mutation, and/or inclusion of genetic 
modifiers in the analysis as a covariate to account for variability in the course of FTD. This will 
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allow better control for factors that vary substantially from person to person in FTD such as age at 
onset or rate of disease progression. 
CONCLUSION 
 Clinical trial research in FTD spectrum disorders is in its infancy. Individuals afflicted with 
these neurodegenerative disorders have numerous unmet needs. Development of new 
pharmacological interventions specifically designed for these individuals is essential as no 
effective disease-modifying treatments or evidence-based symptomatic therapies have been 
identified. Critical examination of previously published RCTs revealed potential explanations for 
their negative results as well as opportunities to improve future endeavours. We hope these 
recommendations, which are based on patient-centered and precision-medicine approaches, will 
help to steer clinical trials in FTD spectrum disorders in a productive direction.  
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FIGURE 1 LEGEND: A graphical representation of the proposed selection and triage process of potential eligible participants for 
future clinical trials in FTD spectrum disorders, based on precision-medicine approaches. First, subjects are assessed clinically to 
determine the presence of a clinical syndrome according to international consensus diagnostic criteria (e.g.: bvFTD). Then, symptomatic 
and asymptomatic subjects undergo genetic testing to identify mutation carriers (e.g.: C9orf72, GRN, MAPT, VCP, and TARDP), as well 
as genetic variants (e.g.: APOE, HLA, MAPT haplotype H1 and TMEM1068B) that may modify age of onset or increase the risk of a 
specific pathological substrate. In the circumstance that potential eligible participants would not want to be informed of their mutation 
status, they could still be able to enroll in clinical trials. Finally, subjects undergo further testing to identify the presence of FTLD-
specific biomarkers and molecular targets (e.g.: progranulin plasma level and CSF tau level). This selection process permits the exclusion 
of subjects with a low risk of developing FTLD and those with non-FTLD pathology, such as AD. Clinical trials can then be conducted 
in a population with a well-characterised disease where the investigational drug’s target is present. 
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FIGURE 2 LEGEND: A graphical representation of the theoretical progression of FTD spectrum disorders over time and potential 
windows of opportunity for pharmacological interventions. 
 
